Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Nattokinase and Improved Clinical Symptoms

Doses used in studies

mg/day: 100 (median 100, IQR 100–100) — 1 study

Safety in these studies

Overall tolerabilityReported
documented that nattokinase was able to improve the clinical symptoms (p < 0.01) without the development of adverse drug reactions or drug interactions
from: Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Dis

1 of 1 paper

Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases.
- 2021-06-13
- Clinical Trial · n = 153
- Nutrients 13(6)
- - Giuseppe Gallelli
  - Giulio Di Mizio
  - Caterina Palleria
  - Antonio Siniscalchi
  - Paolo Rubino
  - Lucia Muraca
  - Erika Cione
  - Monica Salerno
  - Giovambattista De Sarro
  - Luca Gallelli
- PubMed: 34199189
- DOI: 10.3390/nu13062031
1 Insight on
- Improved Clinical Symptoms
- High evidence
- Large Human Trial
- Rigorous Journal
- Clinical
documented that nattokinase was able to improve the clinical symptoms (p < 0.01)
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
100 mg/day per os